A novel translocation t(3;21)(p21;q22) in acute myelogenous leukemia preceding a late-appearing Philadelphia chromosome

Medicine and Dentistry

• Patient 100%
• Therapeutic Procedure 90%
• Nilotinib 80%
• Imatinib 70%
• Acute Myeloid Leukemia 50%
• Bone Marrow 50%
• Drug Megadose 40%
• Cytarabine 40%
• P21 30%
• Vatalanib 30%
• Chemotherapy 20%
• Philadelphia 1 Chromosome 20%
• Pancytopenia 20%
• Caspofungin 20%
• Inpatient 20%
• Case Report 20%
• Chromosome 10%
• Chromosome Analysis 10%
• Adverse Event 10%
• Outpatient 10%
• Spontaneous Remission 10%
• Hydroxyurea 10%
• Combination Therapy 10%
• Amphotericin B 10%
• Treatment Response 10%
• Fluorescence in Situ Hybridization 10%
• Fine-Needle Aspiration 10%
• Antibiotic Therapy 10%
• Real Time Polymerase Chain Reaction 10%
• Chronic Myelogenous Leukemia 10%
• Evaluation Study 10%
• Broad-Spectrum Antibiotic 10%
• Tyrosine-Kinase Inhibitor 10%
• Phosphotransferase Inhibitor 10%
• Aspiration 10%
• Gyrase Inhibitor 10%
• Antifungal Agent 10%
• Lung Biopsy 10%
• Metaphase 10%
• Fludarabine 10%
• Interphase 10%
• Idarubicin 10%
• Antifungal Therapy 10%
• Mitoxantrone 10%
• Amphotericin 10%
• Vorinostat 10%
• Leukocyte Transfusion 10%
• Bone Marrow Examination 10%
• Mucormycosis 10%
• Analysis 10%
• Observation 10%
• Male 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Nilotinib 80%
• Imatinib 70%
• Acute Myeloid Leukemia 50%
• Cytarabine 40%
• Vatalanib 30%
• Philadelphia 1 Chromosome 20%
• Pancytopenia 20%
• Caspofungin 20%
• Hydroxycarbamide 10%
• Adverse Event 10%
• Prognosis 10%
• Remission 10%
• Amphotericin B 10%
• Chronic Myeloid Leukemia 10%
• Protein Tyrosine Kinase Inhibitor 10%
• Gyrase Inhibitor 10%
• Phosphotransferase Inhibitor 10%
• Fludarabine 10%
• Amphotericin 10%
• Vorinostat 10%
• Mitoxantrone 10%
• Antifungal Agent 10%
• Dysplasia 10%
• Mucormycosis 10%
• Idarubicin 10%

INIS

• ph'chromosome 10%